Glatt and Innopharma Labs Partner on Real-Time In-Line Particle Characterization for Batch and Continuous Production - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Glatt and Innopharma Labs Partner on Real-Time In-Line Particle Characterization for Batch and Continuous Production


Glatt and Innopharma Labs have formed a partnership to provide Glatt’s customers access to Innopharma Labs’ non-invasive, real-time 3D particle characterizer, Eyecon, which has the ability to generate live particle size and shape information.


Developed specifically for pharmaceutical processes, the particle characterizer increases process understanding, and subsequently control, in formulation development, scale up, tech transfers, and process optimization in commercial manufacturing of both batch and continuous processes, leading to a reduction of lead times.  


Eyecon is a self-contained portable image capture and analysis sensor that can be mounted to inspection ports of Glatt equipment for in-line, real-time, non-product contact monitoring of particle morphology and size to aid in reducing batch losses and cycle time, improving yields and gain greater control of process end points during granulation, coating, spheronization and continuous fluid bed drying. The imaging analysis collects relevant data for formulation development. Being captured in real-time data helps to gain maximal transparency in the production process for complete documentation.


Eyecon may also be used for static bench-top sample analysis. It can also support process analytical technology and continuous manufacturing of pharmaceutical products.


Source: PR Newswire

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here